Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuPARPed
NCT06607692Phase 2Recruiting
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Sep 2024
- Primary completion
- Jul 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate, olaparib in solid tumor, sponsored by Fundación de Investigación HM Hospitales. Started Sep 2024; status: recruiting.
02
Drugs
lutetium Lu 177 dotatateolaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06607692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607692.